Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
NervGen Pharma Corp
V.NGEN
Alternate Symbol(s):
NGENF
Healthcare
Biotechnology
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a...
therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:NGEN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 06, 2024 2:47pm
NervGen Pharma to Present at the Canaccord Genuity 44th Annu
News; $NGENF NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth ConferenceVancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB
...more
(4)
•••
Nosleep
X
View Profile
View Bullboard History
Comment by
Nosleep
on Jul 11, 2024 8:34pm
RE:RE:Stock options
who cares, you either own it and win with them, or lose with them. Stock is do or die, under .50 cents if drug shows no results, so the options are worthless anyways at that point. If the drug works
...more
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company
posted Dec 21, 2024 9:00am by
Voyageur Pharmaceuticals Ltd
-
|
Voyageur is securing supply chains in North America for barium, iodine and fullerene drug development and is aiming to gain efficiencies in production of contrast media products. The company anticipates this LOI will expand Voyageur’s project portfolio and diversify the Company’s product mix. The global contrast media market is valued at $6.3 billion with GE HealthCare projecting it will double over the next decade. ...read more
(22)
•••
wallpaper2
X
View Profile
View Bullboard History
Comment by
wallpaper2
on Jul 10, 2024 10:03am
RE:Stock options
VERY TACKY !! Gutless move by weak gutless Board.
(44)
•••
greenland
X
View Profile
View Bullboard History
Post by
greenland
on Jun 26, 2024 8:53pm
2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium V.NGEN | 6 days ago Vancouver, British Columbia--(Newsfile
...more
(556)
•••
deepoil0808
X
View Profile
View Bullboard History
Post by
deepoil0808
on Jun 07, 2024 4:05pm
Stock options
The issuance of stock options does not inspire confidence as these options were given away at cost, with no premium in them. I would have issued stock options (sat triple the amount or 3 million
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 06, 2024 6:01pm
New Press Release - NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive stock...
read article.
(556)
•••
deepoil0808
X
View Profile
View Bullboard History
Post by
deepoil0808
on Jun 05, 2024 7:35pm
Safest strategy is to WAIT for results first...then decide.
This stock is a BINARY stock, meaning will be very volatile when results are released. Best strategy is to wait for trial results before buying. If trials fail, then stock will plunge and it
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 05, 2024 8:31am
New Press Release - NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholdersGlenn Ives appointed as Chair of the BoardJohn Ruffolo appointed as Chair of the Audit CommitteeVancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 17, 2024 8:31am
New Press Release - NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical...
read article.
(556)
•••
deepoil0808
X
View Profile
View Bullboard History
Post by
deepoil0808
on May 16, 2024 12:46pm
Sure reads like a very disappointing press release
I think I am reading the tea leaves correctly and that the results will be inconclusive. We learned more on the delay in enrollment. They are having difficulty finding a homogenous group
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 16, 2024 8:31am
New Press Release - NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024Subacute cohort protocol being amended to enhance feasibility and lessen burden on participantsCA$23 million bought deal financing completed in March 2024 provides expected cash runway through...
read article.
(556)
•••
deepoil0808
X
View Profile
View Bullboard History
Post by
deepoil0808
on May 15, 2024 11:32pm
CEO.CA post on a director
A poster brought up issues that one director is having in Court. If true, this type of alledged conduct is very concerning, especially when person is sitting as director of NGEN. Does not
...more
(556)
•••
deepoil0808
X
View Profile
View Bullboard History
Post by
deepoil0808
on May 15, 2024 6:28pm
2 issues of concern???? PP + delays in patients
I read the press releases of the corporation and there are 2 possible concerns: (a) Timing of PP - the corporation said that they needed $$$ so they did PP. But did they
...more
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on Apr 25, 2024 8:53pm
PR Firm
This reeks of desperation. Makes zero sense. If results are positive then it will sell itself. Maybe they are gearing up for a stock offering!
(556)
•••
deepoil0808
X
View Profile
View Bullboard History
Post by
deepoil0808
on Apr 25, 2024 8:38pm
Sedar filings HINT at inconclusive evidence (more testing)?
I conducted a review of the insider buying from February 15th 2024 to date. The date of February 15th is when there were leaks of one patient doing well, followed up later with free
...more
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Viva Gold Reports Strong Initial Assay Results for its Fall 2024 Drill Program at Tonopah Gold Project
Candlestick Patterns All Traders Should Look Out For
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments